New Zealand markets closed

The fight against COVID19

The fight against COVID19

23.40k followers14 symbols Watchlist by TREA

Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.

Curated by TREA

TREA analyses over 100 million data points, interactions, relationships on company research and development activities, allowing investors to quickly gain insight without having to go through complex regulatory filings. Primary data sources include: US FDA (US Food and Drug Administration), US NIH (US National Institutes of Health), USPTO (US Patent and Trademark Office). The search parameters for generating this watchlist were (1) Above sector average Innovation Index score, (2) IP history of at least 5 years (3) COVID19 (4) 2019-nCov (5) SARS-CoV-2, among others.


WatchlistChange today1-month return1-year returnTotal return
The fight against COVID19+1.08%---

14 symbols

SymbolCompany nameLast priceChange% changeMarket timeVolumeAvg vol (3-month)Market cap
JNJJohnson & Johnson182.29+2.63+1.46%4:00 pm GMT-49.37M7.54M479.68B
PFEPfizer Inc.51.59+1.50+2.99%4:05 pm GMT-415.70M24.90M289.47B
ABBVAbbVie Inc.152.34+2.89+1.93%4:03 pm GMT-47.90M7.28M269.20B
SNYSanofi53.42+3.00+5.95%4:00 pm GMT-44.59M2.33M133.41B
GSKGSK plc43.69+0.94+2.20%4:00 pm GMT-43.93M5.75M111.06B
GILDGilead Sciences, Inc.63.08+0.50+0.80%4:00 pm GMT-49.15M8.29M79.12B
REGNRegeneron Pharmaceuticals, Inc.612.49+5.10+0.84%4:00 pm GMT-4815.43k706.23k67.28B
MRNAModerna, Inc.144.27+1.01+0.71%4:00 pm GMT-48.45M6.10M57.38B
TAKTakeda Pharmaceutical Company Limited13.84+0.11+0.80%4:00 pm GMT-42.99M2.69M42.98B
BNTXBioNTech SE134.04+1.75+1.32%4:00 pm GMT-41.02M1.40M32.57B
NVAXNovavax, Inc.51.67-0.14-0.27%4:00 pm GMT-44.83M5.99M4.04B
VIRVir Biotechnology, Inc.24.84-1.05-4.06%4:00 pm GMT-42.85M1.61M3.29B
INOInovio Pharmaceuticals, Inc.1.94-0.07-3.48%4:00 pm GMT-48.87M6.17M444.34M
  • Zacks

    Regeneron (REGN) Gains But Lags Market: What You Should Know

    Regeneron (REGN) closed at $612.49 in the latest trading session, marking a +0.84% move from the prior day.

  • Reuters

    BioNTtech in conflict with regulator over new COVID vaccine approval - WAS

    The launch of German drugmaker BioNTech's vaccine adapted to the Omicron coronavirus variant may be delayed due to a disagreement with the regulator over the approval process, the Welt Am Sonntag (WAS) newspaper reported on Saturday. The regulator should still decide by the end of June whether or not to approve the new vaccine but BioNTech Chief Executive Ugur Sahin does not plan to submit any new clinical trials, WAS reported, citing the Financial Times. The reason for this was that the approval "should go through the same regulatory process as ordinary flu vaccines", which would allow the new COVID-19 vaccine to be delivered in three months, WAS cited Sahin as saying.

  • Zacks

    Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

    In the latest trading session, Novavax (NVAX) closed at $51.67, marking a -0.27% move from the previous day.